Clinical Trial Update: Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab [Phase 2]

View source ↗

Summary

Phase 2 trial update examining biomarkers in urothelial cancer patients treated with pembrolizumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transitional Cell Carcinoma of the Bladder
• Urothelial Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Erasmus Medical Center | Conditions: Transitional Cell Carcinoma of the Bladder, Biomarkers | Phase 2 | Status: UNKNOWN